PROVETOP

Biotinylated Human SLAMF1/SLAM/CD150 Protein

Catalog No: SLAMF1-HB001

Species
Human
Expression System
HEK293
Tag
His, Avi

Product overview

Recombinant Biotinylated Human SLAMF1/SLAM/CD150 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Ala21-Pro237 (UniProt accession: Q13291-1).

Product Details

Molecular Aliases
CDw150; IPO-3; CD150; SLAMF1; SLAM
Protein Length
Ala21-Pro237
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 27.2 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
State
Lyophilized
Storage Conditions
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution Advice
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data Display

Bis-Tris PAGE
SLAMF1-HB001 Bis-Tris-PAGE-white result

Biotinylated Human SLAMF1 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
SLAMF1-HB001 SEC-HPLC result

The purity of Biotinylated Human SLAMF1 is greater than 95% as determined by SEC-HPLC.

Background

SLAMF1/CD150 receptor is a founder of signaling lymphocyte activation molecule (SLAM) family of cell-surface receptors. It is widely expressed on cells within hematopoietic system. In hematologic malignancies CD150 cell surface expression is restricted to cutaneous T-cell lymphomas, few types of B-cell non-Hodgkin's lymphoma, near half of cases of chronic lymphocytic leukemia, Hodgkin's lymphoma, and multiple myeloma.

References

  1. Gordiienko I, Shlapatska L, Kovalevska L, Sidorenko SP. SLAMF1/CD150 in hematologic malignancies: Silent marker or active player? Clin Immunol. 2019 Jul;204:14-22. doi: 10.1016/j.clim.2018.10.015. Epub 2018 Oct
  2. PMID:
  3. Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support